Enable Accessibility Enable Accessibility

Retail Investor Resource Hub 

Welcome to Takeda’s resource hub for retail investors. Here you can sign up for email alerts, stay up to date on financial results and corporate milestones, and learn how Takeda is delivering on our commitment to patients, our people, and the planet. 

Stay up to date on our covid-19 efforts.

Please wait...

Please wait...

Sign up for email alerts from Takeda

Takeda Highlights



Approx, Revenue


As of March 2021. References: FY2020 Q4 Investor Presentation; Corporate Overview
1USD included for reference, calculated at JPY/USD of 110.6
2Non-IFRS measure. Further information on this and other Takeda Non-IFRS measures is posted on Takeda’s investor relations website
3As defined by Tokyo Stock Exchange Securities Listing Regulations



Investor Events

Check back for event calendar updates or sign up for email alerts straight to your inbox. 




Takeda has published its 2021 Annual Integrated Report

Find out how our financial and other impacts are creating value in the short, medium and long term, and the focus areas we believe are most important for the stakeholders and communities we serve. READ MORE



Innovation at Takeda

Our world-class R&D engine is focused on developing medicines and vaccines that will have a lasting impact on society and can make a critical difference to the lives of patients with limited or no options for treatment.



Frequently Asked Questions

General Information

Our 145th Ordinary General Meeting of Shareholders was held on June 29, 2021. Please visit our Annual Shareholders Meeting page for more information.


Stock Information

You may contact a licensed stockbroker or go through any registered broker-dealer to purchase shares of Takeda.

Takeda’s common shares are traded on the Tokyo Stock Exchange using stock code “4502.” Our ADSs are traded on the New York Stock Exchange using the symbol “TAK”. 

An American Depositary Receipt (ADR) is a certificate representing ownership of American Depositary Shares (ADSs) in a non-U.S. corporation. They include the right to attend and vote at AGMs, the receipt of dividends, and other common shareholder rights. One ADS represents 0.5 shares of Takeda’s common stock.  

Click here to learn more about Takeda’s historic share price performance.

Takeda’s largest shareholders and other share data, as most recently reported, can be found here. 


Dividend Information

Takeda has maintained a well-established dividend policy of 180 yen per share annually. Information on historical dividends paid by Takeda can be found here

Takeda’s  dividend payments have historically been issued on a semi-annual basis in June and December. The record date for year-end dividends is March 31 of each year. The record date for interim dividends is September 30 of each year. 


Financial Information

Takeda’s fiscal year ends on March 31st. You can find our earnings materials and dates on our financial results webpage.

Takeda’s official reporting currency is the yen.

Takeda follows the International Financial Reporting Standards, or IFRS, for its financial reporting.

For historic financial highlights of Takeda, please refer to our Financial Highlights page.


Additional Information

To send a comment or question to Takeda Pharmaceutical Company Limited, please visit: https://www.takeda.com/who-we-are/contact-us/

To subscribe to email alerts from Takeda, please use the form at the top of this page.


For feedback or inquiries, please visit https://www.takeda.com/who-we-are/contact-us/

Select the alerts you’d like to receive: * Indicates required field

At least one alert must be selected

Select one of the following:

Takeda will use the contact information you entered above to provide you with the investor related materials you requested. In order to best serve and effectively communicate with you, Takeda may also use your personal data for advertising purposes, such as serving you targeted advertisements related to the information you requested.  For more information on how Takeda processes your personal data and your rights related to this processing, please refer to our Privacy Notice and Terms of Use.